Oramed Pharmaceuticals Inc.
ORMPHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. Valued at $169.0M, ORMP is a micro-cap name in its sector. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
Market Cap
$169.0M
Beta
1.28
P/E (TTM)
1.00
P/E (Fwd)
-51.63
EPS (TTM)
$4.13
EPS (Fwd)
$-0.08
ROE
74.2%
ROA
-3.4%
Cash
$50.6M
Total Debt
$733,000
Free CF
$2.5M
52W Change
74.3%
Annual Financials
Cash vs Debt
Where ORMP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ORMP finished 3.33% below its 150-day moving average ($4.20) and 2.01% above its 200-day moving average ($3.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ORMP overbought or oversold?
At the October 20, 2026 close, ORMP's RSI(14) was 21.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Oramed Pharmaceuticals Inc. holds $50.6M in cash against $733K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $2.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 74.2% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.7M (2021) to $2.0M (2025), a 26% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Oramed Pharmaceuticals Inc.'s trajectory.